Sunshine Biopharma Inc (SBFM)

[TRUSTUNITS1000000]

Terrible

[TRUSTUNITS1000000]

Interesting cash balance

[TRUSTUNITS1000000]

Terrible

[hssbwwmp]

It looks like the 40:1 RS filing today is the only way for SBFM to up the price at least for a few days. They can't seem to get anything positive done with their drug "pipeline" to help the price!

https://sunshinebiopharma.com/propretary-drugs/

[Suomalainen]

"Based on 99,452,861 Common Stock outstanding based on the Issuer’s filings with the Securities and Exchange Commission and related information." ?? No end in site for the ever repeated RS on this. Criminal really.

[Jean Naymar]

The real criminals are the 3 mobsters aka SBFM management. They are taking all the moneys! Their employee's money, recent whales investors and obviously their shareholders. Rosen actually warned us about them 2 years ago, does it make him a good guy, probably not, but here we are and he was absolutely right

[radly]

Bret Rosen doesn't need to be a concern. Just making a remark since he had dealings with this company and pumping it in the past! Just wanted to know if anyone knew he was such a con/criminal.

[Jean Naymar]

How is that relevant to the SBFM sh*t show? Bret Rosen is the least of my concerns right now

[radly]

Who new Bret Rosen was such a con and criminal!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173921809

[TRUSTUNITS1000000]

0.0533 whatttttttttttt

[hssbwwmp]

Clearly something is wrong with this company when the share price drops to $.05 and they don't address the constant decline. You may be the last one here if things don't get better soon.

[TRUSTUNITS1000000]

Board is getting quiet

[TRUSTUNITS1000000]

Wonder if a buy

[TRUSTUNITS1000000]

Made a while back

[TRUSTUNITS1000000]

Wonder if a buy

[TRUSTUNITS1000000]

Management must be rich

[TRUSTUNITS1000000]

Interesting financing all the time

[TRUSTUNITS1000000]

Is this a scam

[TRUSTUNITS1000000]

Terrible what happened here, disgraceful

[TRUSTUNITS1000000]

0.0636 a few days ago 20 sssssssss

[aldo]

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering
https://finance.yahoo.com/news/sunshine-biopharma-inc-announces-closing-141500733.html

[aldo]

11 Hyper-Growth Stocks Billionaires Are Loading Up On.
Thieves.
When they published this article, they knew very well that new stocks were about to be released. such a transaction takes several weeks to be realized. Everyone has to make decisions according to what they do and not according to what they say. Interestingly, today's chart shows a huge accumulation.

[Money Management]

Going to Jail @ Old Age ,stealing money spreading false claims about a miracle drug.

[aldo]

https://sunshinebiopharma.com/wp-content/uploads/20240209_SBFM_S1-A1.pdf
We are also offering to each purchaser of Units that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% of our
outstanding common stock immediately following the consummation of this offering, the opportunity to purchase Units consisting of one pre-
funded warrant (in lieu of one share of common stock, each a “Pre-Funded Warrant”), one-tenth (1/10) of a Series A Warrant and two-tenths
(2/10) of a Series B Warrant. Subject to limited exceptions, a holder of Pre-Funded Warrants will not have the right to exercise any portion of its
Pre-Funded Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, such
limit may be increased to up to 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise.
Each Pre-Funded Warrant will be exercisable for one share of common stock. The purchase price of each Unit including a Pre-Funded Warrant
will be equal to the price per Unit including one share of common stock, minus $0.001, and the remaining exercise price of each Pre-Funded
Warrant will equal $0.001 per share. The Pre-Funded Warrants will be immediately exercisable (subject to the beneficial ownership cap) and may
be exercised at any time until all of the Pre-Funded Warrants are exercised in full. For each Unit including a Pre-Funded Warrant we sell (without
regard to any limitation on exercise set forth therein), the number of Units including a share of common stock we are offering will be decreased on
a one-for-one basis.
This prospectus also includes the shares of common stock issuable upon exercise of the Series A Warrants, Series B Warrants, and the Pre-Funded
Warrants.
The common stock and Pre-Funded Warrants can each be purchased in this offering only with the accompanying Series A Warrants and Series B
Warrants that are part of a Unit, but the components of the Units will be immediately separable and will be issued separately in this offering. See
“Description of Capital Stock” in this prospectus for more information.
Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “SBFM.” The last reported sale price of our common
stock on Nasdaq on February 6, 2024 was $0.255 per share. There is no established public trading market for the Series A Warrants, Series B
Warrants, or the Pre-Funded Warrants, and we do not intend to list the Series A Warrants, Series B Warrants, or the Pre-Funded Warrants on any
national securities exchange or trading system. Without an active trading market, the liquidity of the Series A Warrants, Series B Warrants, and the
Pre-Funded Warrants will be limited.
The final public offering price of the Units will be determined through negotiation between us and the underwriter, based upon a number of
factors, including our history and our prospects, the industry in which we operate, our past and present operating results, the previous experience
of our executive officers and the general condition of the securities markets at the time of this offering.
We have granted Aegis Capital Corp., as underwriter, an option, exercisable for 45 days from the closing date of this offering, to purchase up to
5,882,353 additional shares of common stock and/or Pre-Funded Warrants, representing 15% of the shares of common stock and/or Pre-Funded
Warrants sold in the offering, and/or up to 588,235 Series A Warrants, representing 15% of the Series A Warrants sold in the offering, and/or up to
1,176,470 Series B Warrants, representing 15% of the Series B Warrants sold in the offering. The underwriter may exercise the over-allotment
option with respect to shares of common stock only, Pre-Funded Warrants only, Series A Warrants only, Series B Warrants only, or any
combination thereof.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 4 of this prospectus for a discussion of
information that should be considered in connection with an investment in our securities.

[aldo]

39,215,687 Units, Each Unit Consisting of One Share of Common Stock or One Pre-Funded Warrant to Purchase One Share
of Common Stock, one-tenth of a Series A Warrant to Purchase one Share of Common Stock and two-tenths of a Series B Warrant to
Purchase one Share of Common Stock
11,764,706 Shares of Common Stock Underlying the Series A and Series B Warrants
Sunshine Biopharma, Inc. is offering, on a firm commitment, underwritten basis, 39,215,687 units (the “Units”), each Unit consisting of one share
of our common stock, $0.001 par value per share, one-tenth (1/10) of a Series A warrant (“Series A Warrant”) to purchase one share of common
stock and two-tenths (2/10) of a Series B warrant (“Series B Warrant”) to purchase one share of common stock, at an assumed public offering
price of $0.255 per Unit, which was the last reported sale price of our common stock on The Nasdaq Capital Market, or Nasdaq, on February 6,
2024.
The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. Each Series A Warrant offered hereby is
immediately exercisable on the date of issuance at an exercise price of $3.825 (assuming an offering price of $0.255 per Unit) per share of
common stock, or pursuant to alternate cashless exercise option, and will expire two-and-a-half years from the closing date of this public offering.
Each Series B Warrant offered hereby is immediately exercisable on the date of issuance at an exercise price of $4.335 (assuming an offering price
of $0.255 per Unit) per share of common stock, and will expire five years from the closing date of this public offering.
Under the alternate cashless exercise option of the Series A Warrants, beginning on the date of the Warrant Stockholder Approval (described
below), the holder of the Series A Warrant, has the right to receive an aggregate number of shares equal to the product of (x) the aggregate number
of shares of common stock that would be issuable upon a cash exercise of the Series A Warrant and (y) 2.0. In addition, beginning on the date of
the Warrant Stockholder Approval, the Series A Warrants and Series B Warrants will contain a reset of the exercise price to a price equal to the
lesser of (i) the then exercise price and (ii) lowest volume weighted average price for the five trading days immediately preceding and immediately
following the date we effect a reverse stock split in the future with a proportionate adjustment to the number of shares underlying the Series A
Warrants and Series B Warrants. Finally, beginning on the date of the Warrant Stockholder Approval, with certain exceptions, the Series B
Warrants will provide for an adjustment to the exercise price and number of shares underlying the Series B Warrants upon our issuance of our
common stock or common stock equivalents at a price per share that is less than the exercise price of the Series B Warrant.
The alternate cashless exercise option included in the Series A Warrants and the other adjustment provisions described in the above paragraph
included in the Series A Warrants and Series B Warrants will be available only upon receipt of such stockholder approval as may be required by
the applicable rules and regulations of the Nasdaq Capital Market to permit the alternate cashless exercise of the Series A Warrants and the other
adjustment provisions described in the above paragraph included in the Series A Warrants and Series B Warrants (the “Warrant Stockholder
Approval”). In the event that we are unable to obtain the Warrant Stockholder Approval, the Series A Warrants will not be exercisable using the
alternate cashless exercise option and the other adjustment provisions described in the above paragraph included in the Series A Warrants and
Series B Warrants will not be effective, and therefore the Series A Warrants and Series B Warrants may have substantially less value. See the Risk
Factor on page 15 relating to the Series A Warrants and Series B Warrants and Warrant Stockholder Approval, and see the section entitled
“Warrant Stockholder Approval” on page 40 for additional details regarding the Warrant Stockholder Approval

[TRUSTUNITS1000000]

Terrible what happened here

[TRUSTUNITS1000000]

Not much volume

[TRUSTUNITS1000000]

Sell me 0.0001

[TRUSTUNITS1000000]

Wowwwwww dropping a lot🥳

[TRUSTUNITS1000000]

Where are the mice

[TRUSTUNITS1000000]

Made a while back

[TRUSTUNITS1000000]

Interesting sales

[TRUSTUNITS1000000]

Reverse split again properly

[TRUSTUNITS1000000]

To zero speculating, interesting

[TRUSTUNITS1000000]

Dropping

[TRUSTUNITS1000000]

0.0000000000 lol

[TRUSTUNITS1000000]

Millions in the bank

[TRUSTUNITS1000000]

Millions in the bank

[TRUSTUNITS1000000]

Dropping

[Lumberg]

We're all grabbing our ankles on this turd

[mokage]

I've been in this turd through all the BS and am left down $1k and own 7 stocks lol. Win some lose some

[TRUSTUNITS1000000]

Could this be the bottom

[TRUSTUNITS1000000]

Wonder about this company

[TRUSTUNITS1000000]

Interesting share structure

[TRUSTUNITS1000000]

Any interesting drugs being worked on. I thought good news with mice, they must have died

[TRUSTUNITS1000000]

In this a while back and made

[TRUSTUNITS1000000]

Down today

[TRUSTUNITS1000000]

Interesting post

[hssbwwmp]

Seems like a billionaire could do a buyout of SBFM and then turn it into a major biopharmaceutical company?

[TRUSTUNITS1000000]

Interesting sales